Demographics and SLE features at baseline.
| Measure | n | Arithmetic Mean (SD) |
|---|---|---|
| Age, yrs | 98 | 14.7 (0.5) |
| Disease duration, yrs | 98 | 1.5 (2.0) |
| Current medications | ||
| Prednisone (mg/day) | 81 | 15.1 (1.8) |
| Azathioprine, mycophenolate mofetil, methotrexate | 47 | |
| Cyclophosphamide | 6 | |
| Hydroxychloroquine | 73 | |
| NSAID | 24 | |
| At least 1 antihypertensive medication | 38 | |
| Biopsy-proven lupus nephritis† | 54 | |
| Disease activity | ||
| SLEDAI-2K score | 98 | 4.8 (4.4) |
| BILAG score* | 4.9 (5.2) | |
| Disease damage | ||
| SDI score** | 98 | 0.42 (0.1) |
↵† WHO Class 2, 3, 4, 5, 6 was present in 4, 12, 28, 9, and 1 patient, respectively.
↵* British Isles Lupus Activity Group index; alphabetical scores converted as follows: A = 9; B = 3; C = 1; D or E = 0.
↵** Systemic Lupus International Collaborating Clinics/ACR Damage Index. NSAID: nonsteroidal antiinflammatory drugs; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index, 2000.